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Summary Human liver carcinoma cells (BEL-7404) and human KB adenocarcinoma cells were selected by
stepwise increases in cisplatin. Drug sensitivity assays indicated that the IC", value for 7404-CP7.5 cells was
49figml-I cisplatin, I11-fold higher than for the parental hepatoma cells. The IC50 value for KB-CP10 cells
was 38 iLg ml-I cisplatin, which is 1152-fold higher than for the parental KB cells. The 7404-CP7.5 cells were
cross-resistant to methotrexate (39 x), 5-fluorouracil (23 x) and 6-mercaptopurine (13 x), but were sensitive
to drugs which are known substrates for the multidrug transporter (P-glycoprotein), including colchicine,
vinblastine and actinomycin D. Similar cross-resistance patterns were observed for KB-CPIO cells. No
evidence of DNA amplification or expression of the MDRI gene was found. One-dimensional sodium dodecyl
sulphate-polyacrylamide gel electrophoresis showed increases in 52 kDa protein(s) in both the soluble
cytosolic and crude membrane fractions in 7404-Cr cells and in KB-CPF cells. The amount of 52 kDa protein
was proportional to the degree of resistance of the 7404-CP cells to cisplatin. Two-dimensional gel analysis
demonstrated that two polypeptides of molecular mass 52 and 50 kDa were overexpressed in the membrane
fractions in both 7404-CP20 and KB-CP20 cells. Using amino acid microsequencing and Western blotting, the
major 52 kDa protein was identified as the mitochondrial heat shock protein hsp60. Two-dimensional gels of
[35S]methionine-labelled polypeptides showed many other changes, including reduction in soluble proteins of
approximately 57 kDa molecular weight in KB-CP20 cells, and of 35 kDa in both 7404-CP20 and KB-CP20
cells. These results suggest that alterations of certain proteins occur commonly in cisplatin-resistant cells,
particularly proteins of molecular weight 52 and 50 kDa.
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cis-Diamminedichloroplatinum II (cisplatin) has become a
major chemotherapeutic agent in clinical treatment of
tumours since it was found to have anti-cancer activity two
decades ago. Cisplatin is used particularly for treatment of
solid tumours, such as testicular cancer, ovarian cancer, blad-
der cancer, cancer of the head and neck and small-cell lung
carcinomas (Loehrer and Einhorn, 1984). However, as with
all anti-cancer drugs, many tumours show intrinsic resistance
to cisplatin or develop resistance after initially responding to
treatment. One well-studied example is the development of
multidrug resistance (MDR) to agents such as vinca alka-
loids, anthracyclines, taxol and epipodophyllotoxins. Multi-
drug resistance is commonly associated with expression of
the MDR1 gene, which encodes the 170 000M, membrane
P-glycoprotein, an ATP-dependent efflux pump which pre-
vents accumulation of drugs in resistant cells (Gottesman and
Pastan, 1993). Resistance to cisplatin does not result from
overexpression of the MDR1 gene and has been postulated to
be associated with several different cellular changes, including
reduced accumulation of the drug (Richon et al., 1987),
increased levels of intracellular metallothionein and
glutathione or enzymes involved in glutathione metabolism
(Moscow and Cowan, 1988; Kasahra et al., 1991; Shellard et
al., 1991; Timmer-Bosscha et al., 1992), including elevated
expression of mRNAs for 7-glutamylcysteine synthetase and
'y-glutamyltranspeptidase (Godwin et al., 1992), increases in
thymidylate synthase (Newman et al., 1988), enhanced DNA
repair (Plooy et al., 1985; Masuda et al., 1988) or the
presence of DNA-binding proteins recognising damaged
DNA (Chu and Chang, 1990). The exact mechanisms of
resistance to cisplatin during chemotherapy requires further
elucidation.
A number of cell lines with different levels of resistance to
cisplatin have been isolated from human ovarian carcinoma,
small-cell lung cancer and colon cancer, as well as from
several murine cell lines. To further understand intrinsic
resistance to cisplatin and the development of high-level resis-
tance to cisplatin, we have established a series of highly
cisplatin-resistant cell lines from an intrinsically cisplatin-
resistant human liver carcinoma cell line, BEL-7404, and
from cisplatin-sensitive KB adenocarcinoma cells to explore
common features related to cisplatin resistance in two
different human cell lines.
Materials and methods
Cell lines and cell culture
The human liver carcinoma cell line, BEL-7404, was selected
for resistance to cisplatin. The biological characteristics of
this cell line have been previously described in detail (Shen
and Chen, 1985). A series of cisplatin-resistant BEL-7404
populations were selected by stepwise increases in cisplatin
concentration from 300 ngml-' to 20jig ml-' of medium
over a period of 24 months. For comparison purposes, the
human epidermoid carcinoma cell line KB-3-1, a subclone of
the human HeLa cervical adenocarcinoma cell line, was muta-
genised with 200 jgml' ethyl methanesulphonate (EMS) for
24 h, and also selected for resistance to cisplatin by stepwise
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December 1994increases in cisplatin from 200 ng ml1' to 20figml1' of
medium. The KB-Cl.5 cell line (Shen et al., 1986) is a
colchicine-selected MDR1-expressing derivative maintained in
1.5pgml-' colchicine and was used for comparison of pro-
tein patterns. All cell lines were grown as monolayer cultures
at 37°C in 5% carbon dioxide, using Dulbecco's modified
Eagle medium with 4.5 g I1 glucose (Gibco), supplemented
with L-glutamine, penicillin, streptomycin and 12% fetal
bovine serum (Whittaker, MA Bioproducts).
Drugs and chemicals
Cisplatin was a gift from the Bristol-Myers Research Labor-
atory and Johnson Matthey. Colchicine, vinblastine, doxo-
rubicin, actinomycin D, melphalan, methotrexate, 5-fluorou-
racil (5-FU) and 6-mercaptopurine (6-MP) were purchased
from Sigma. Mitomycin C was obtained from Calbiochem.
VP-16 was from the Bristol-Myers Research Laboratory.
Drug sensitivity assay
The dose-response curves of the hepatoma cisplatin-resistant
cell lines and the KB adenocarcinoma cells were determined
by seeding 5 x 104 cells in 1 ml of medium in each well of a
24-well dish. At the time of seeding, the chemicals at desired
concentrations were introduced into the cell medium. After
incubation for 3 days, the cells were counted with a Coulter
counter. An IC50 value was measured as the concentration of
drug reducing the number ofcells after 3 days to 50% of that
in control (drug-free) medium. A relative resistance factor for
each drug was determined by dividing the IC50 value of the
drug for the cisplatin-resistant cell lines by that for the
appropriate parental cell lines, BEL-7404 or KB-3-1. The
values are means of triplicate determinations.
Cytosolfractions andprotein electrophoresis
Cells were harvested at log phase, washed twice with cold
PBS and homogenised in hypotonic solution (10 mM Tris,
2 mM magnesium chloride, 1 mM EDTA, pH 8.0) with about
20 strokes of a Dounce homogeniser. Samples were checked
under a phase-contrast microscope, and showed more than
80% of cells broken. The cytosol fractions were separated by
centrifugation at 800 g for 5 min. The supernatant was fur-
ther centrifuged at 35 000 r.p.m. for 30 min. The pellet from
this 35 000 r.p.m. centrifugation is referred to as the crude
membrane fraction and was dissolved in SDS buffer (5%
SDS, 10% glycerol, 60 mM Tris, pH 6.8, 5% 2-mercapto-
ethanol) for gel analysis. The supernatant is referred to as the
soluble cytosol fraction. Sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE) (Laemmli, 1970)
using 6%, 8%, 10% and 12.5% acrylamide gels was per-
formed at least twice for each sample to visualise the
differences in protein patterns among cisplatin-resistant cell
lines and their parental cells. Two-dimensional electro-
phoresis was performed according to the method of O'Farrell
et al. (1977) by Kendrick Labs (Madison, WI, USA). To
label cells with methionine, cells were plated at a density of
4 x 106 per 90 mm dish in fresh Dulbecco's modified Eagle
medium containing 12% fetal bovine serum for 8 h, then
labelled for 16 h in 5 ml of methionine-free medium contain-
ing 5% fetal bovine serum and 1 mCi of [35S]methionine
(ICN). The cells were collected by centrifugation at
1000 r.p.m. for 5 min and cytosolic soluble fractions and
crude membrane fractions were prepared as described
above.
Amino acidmicrosequencing and immunoblot reaction
The desired polypeptide spots for amino acid sequencing
were run on an ABI 477 Sequencer by Protein Structure
Laboratory, University of California at Davis. Mouse
monoclonal antibodies specific for human hsp6o and hsp7o
were purchased from StressGene (Victoria, Canada). For
immunoblotting, the cytosolic soluble proteins were subjected
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to 10% mini-SDS-PAGE, and transferred onto nitrocellu-
lose in a BioRad Transblot device. The blots were reacted
with desired antibodies separately, then visualised using the
ECL kit (Amersham) according to the manufacturer's in-
structions.
Results
Establishment ofcisplatin-resistant linesfrom human liver
carcinoma BEL-7404 cells
The human liver carcinoma cell line, BEL-7404, was adopted
for the selection of cisplatin resistance because this cell line
shows little expression of the MDR1 gene and a higher level
of intrinsic resistance to cisplatin than KB-3-1 cells (Shen et
al., 1991). After 2 weeks ofexposure to 300 ngml-' cisplatin,
a few colonies appeared in the presence of cisplatin. Cells
were trypsinised and the whole cell population was pooled
and designated 7404-CP.3 (i.e. BEL-7404 cells growing in
medium containing 0.3 fgml-' cisplatin). Over a period of
18 months, cisplatin was increased in steps (see Figure la)
and resistant colonies were pooled as above until the
hepatoma cells grew in 7.5 iLg ml-' cisplatin (CP7.5). A sub-
population of the CP7.5 cells was cultured in drug-free
medium for different lengths of time to see if the resistant
phenotype of the cells would be reversed. For example, the
abbreviation dfl55 stands for drug-free for 155 days. For
comparison, human adenocarcinoma KB-3-1 cells were
selected stepwise in increasing concentrations of cisplatin as
shown in Figure lb. The cisplatin-resistant cell line, KB-CP5
(maintained in 5 jigml-' cisplatin), and its partially reverted
cell line, KB-CP5-df365 (drug free for more than 1 year),
were used for these biochemical studies. In addition, KB-
CPIO and KB-CP20 cell lines were also developed from
KB-CP5 and maintained in 10 and 20ltg ml-' cisplatin
respectively.
Cisplatin resistance levels
The killing curves shown in Figure 2a indicate the resistance
levels of the human hepatoma cell line, BEL-7404, and its
cisplatin-selected resistant cell lines. The KB-3-1 cell line and
its CPr cell lines are also shown in Figure 2b. The relative
resistance level for 7404-CP7.5 was 111-fold higher than for
its parental cell line BEL-7404. The first-step cisplatin-
resistant hepatoma CPr cell line, 7404-CP.3, and the inter-
mediate steps, 7404-CPI and 7404-CP5, are 18.3-, 33.4- and
71.6-fold more resistance to cisplatin than their parental cell
line, BEL-7404, respectively. The 7404-CP7.5-dfl55 cell line,
maintained in cisplatin-free medium for 155 days, still main-
tained a resistance level of 31.2-fold, equivalent to that of
7404-CPI. KB-CP-10, and its earlier step resistant line, KB-
CP5, were 1152 and 787 times more resistant than the paren-
tal KB-3-1 cells respectively. However, the IC50 value of
7404-CP7.5 was 49 Lgml-, which was higher than the KB-
CPIO cells (38;Lgml-'). As previously noted, the hepatoma
cells exhibited higher basal levels of resistance to cisplatin
than the KB cells (Shen et al., 1991).
Cross-resistance levels
To determine the cross-resistance patterns in both hepatoma
and KB cell lines, several agents were examined. The patterns
of cross-resistance in parental and cisplatin-resistant human
liver carcinoma cells are listed in Table I. The 7404-CP7.5
cells were sensitive to MDR-related drugs, such as colchicine,
vinblastine and actinomycin D, but somewhat resistant to
doxorubicin and melphalan, an alkylating agent. No cross-
resistance to hydroxyurea and VP-16 could be detected in
7404-CP7.5 cells. However, the hepatoma cisplatin-resistant
cells showed high levels of resistance to methotrexate (39-
fold) and to 5-fluorouracil (23-fold). The resistance of these
cells to 6-mercaptopurine was about 13-fold. A similar pat-
tern of resistance was found for the cisplatin-resistant KB cellCross-esistance and protein changes inCPrcells 00 D-wShen etal
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a
BEL-7404 First step ofselection with
300 ng ml-1 cisplatin without mutage.l
7404.CP3 (cells growing in 300 ng mi-1 cisplatin)
Three steps of increasing concentrations of cisplatin
7404-CP1 (cells growing in 1 gg mi1 cisplatin)
Eight steps of increasing concentrations of cisplatin
7404-CP7.5 (cells growing in 7.5 gg ml-' cisplatin)
Multiple steps of increasing concentrations ofcisplatin
fl 7404-CP20 (cells growing in 20 igg mi-l cisplatin)
7404-CP7.5-df155 (7404-CP7.5 cells cultured in drug-free medium for 155 days)
b
KB-3-1 Mutagenised with 200jg ml=1 EMS, then selected with
200 ng ml-' cisplatin medium
Multiple steps of increasing concentrations ofcisplatin
KB-CP5 (cells growing in 5jig ml-' cisplatin)
[ Five steps of increasing concentrations ofcisplatin
KB-CP10 (cells growing in 10gig ml-1 cisplatin)
Multiple steps of increasing concentrations ofcisplatin
KB-CP20 (cells growing in 20jgg ml-1 cisplatin)
KB-CP5--df365 (KB-CP5 cells cultured in drug-free medium for 365 days)
Figure 1 Flow diagram showing the derivation of cisplatin-resistant cell lines isolated from unmutagenised and mutagenised
human cell lines by ethyl methanesulphonate (EMS). (a) Human liver carcinoma cell line BEL-7404; (b) human cervical epidermoid
carcinoma cell line, HeLa subclone KB-3-1.
Table I Patterns of cross-resistance in parental and cisplatin-resistant lines ofhuman
liver carcinoma cells and KB cells
Chemicals BEL-7404 7404-CP7.5 RRa KB-3-1 KB-CPIO RRa
IC50 (ngml1) IC_v (ngml-)
Cisplatin 0.44 49.0 111.0 0.033 38.0 1152.0
Colchicine 4.3 3.7 0.86 2.0 3.5 1.8
Vinblastine 4.5 3.8 0.84 2.6 4.4 1.7
Doxorubicin 38.0 122.0 3.20 38.0 155.0 4.1
Actinomycin D 16.0 12.1 0.76 4.5 11.2 2.5
Mitomycin C 450.0 420.0 0.93 1.7 13.0 7.6
5-Fluorouracil 69.5 1600.0 23.0 200.0 930.0 4.7
6-Mercaptopurine 22.5 290.0 13.0 95.0 1000.0 11.0
Melphalan 2420.0 6400.0 2.6 254.0 2920.0 12.0
Methotrexate 25.5 1000.0 39.0 4.0 80.0 20.0
VP-16 265.0 290.0 1.1 115.0 72.0 0.62
Hydroxyurea 92.0 100.0 1.1 30.0 110.0 3.6
'RR (relative resistance) was determined by dividing the ICs value (or ICIo value for
mitomycin C) of the drug for cisplatin-resistant 7404-CP7.5 or KB-CP1O cells by that
for the parental cell line, BEL-7404 or KB-3-1 cells respectively. The 7404-CP7.5 cell
line was maintained in medum containing 7.5jugml-' cisplatin; the KB-CP1O cell line
was maintained in medium containing 10ligml-' cisplatin.
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Figure 2 Dose-response curves of the human cisplatin-resistant
cell lines compared with their drug-sensitive parental cell lines
were measured as described in Materials and methods. (a) BEL-
7404 series: *, BEL-7404; 0, 7404-CP7.5; 0, 7404-CP7.5-df155;
0, 7404-CP.3; A, 7404-CPI. (b) KB-3-1 series: *, KB-3-1; 0,
KB-CPS; 0, KB-CPIO.
lines. However, the KB-CP1O cells were also somewhat cross-
resistant to mitomycin C, and the 7404-CP7.5 cells were
not.
Protein patterns detected by one-dimensional SDS-PAGE
Cytosolic soluble fractions isolated from sensitive and cis-
platin-resistant cell lines were analysed by one-dimensional
protein electrophoresis, followed by Coomassie blue staining.
Figure 3 shows that alterations in the amounts of specific
polypeptides could be detected in several regions. A 90 kDa
protein band was increased in the 7404-CPF cells as compared
with the parental cell line BEL-7404, but not obviously
changed in the KB-CP20 cells. However, the density of pro-
teins of molecular weight 52 kDa was increased in the 7404
CP20 cells and slightly increased in the KB-CP20 cells by
2.5-fold and 1.3-fold respectively as determined by scanning
using AMBIS QuantProbe Software, and the results are
shown in Figure 5a. The cell line 7404-CP20-dfl55 main-
tained in the absence of cisplatin for 155 days still retained
levels similar to its parental resistant cell line 7404-CP20.
Reduction of protein bands also occurred in the cisplatin-
resistant cell lines. A band of approximately 35 kDa in both
7404-CP20 and KB-CP20 cells was less dense than in the
parental cell lines, while a dramatically reduced band at
57 kDa was only observed in the KB-CP20 cells.
Protein changes were also found in the pelleted crude
membrane fractions, as shown in Figure 4. KB-C1.5 is a
colchicine-resistant cell line which overexpresses the MDR1
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gene as indicated by an arrow (P170), which served as a
control in this work. One common feature found in 7404-CPr
and KB-CPr cells is an overexpressed 52 kDa protein(s). This
protein(s) was reduced in amount in KB-CP5-df365 cells
which were maintained in cisplatin-free medium for more
than 1 year and have lost some of their cisplatin resistance.
Elevated amounts of the 52 kDa protein(s) appeared to be
associated with increased cisplatin resistance to the 7404_CPr
cell lines. A protein(s) of approximately 90 kDa was in-
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Figure 3 Ten per cent SDS-PAGE of cytosolic soluble proteins
followed by Coomassie blue staining. Cytosolic proteins were
prepared as described in Materials and methods. Aliquots of
501tg of total protein from each cell line were loaded as
indicated. Arrows indicate the molecular mass in kDa. Note that
the 52 kDa proteins were elevated in both the 7404-CP20 and
KB-CP20 cells.
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creased in amount in KB-CP10 cells, and slightly in 7404-CPr
cells. Reduction of a 48 kDa protein was observed in both
hepatoma and KB cisplatin-resistant cell lines.
As shown in the histograms in Figure 5b, the 7404-CP.3
cell line, which was the first-step cisplatin-resistant hepatoma
subline maintained in 300 ngml1- cisplatin, showed about a
45% increase intensity in the 52 kDa protein as compared
with its parental cell line BEL-7404, while 7404-CPI and
7404-CP7.5, which were maintained in 1 and 7.5 jgml-
cisplatin, showed a 100% and 140% increase respectively. In
the KB-CPIO cells, however, only a 55% increase was found
when compared with the parental KB-3-1 cells, which had a
higher basal level of this protein. There were no obvious
differences between KB-3-1 cells and an MDRl-expressing
cell line, KB-Cl.5 (Figure 5b).
Two-dimensional gel electrophoresis ofmethionine-labelled
proteins in cisplatin-resistant cells
To characterise further the protein alterations in cisplatin-
resistant cell lines, cell proteins were radiolabelled with
[35S]methionine for 16 h and analysed by high-resolution two-
dimensional gel electrophoresis. Among hundreds of [35S]-
methionine-labelled proteins separated on these two-dimen-
sional gels, a number ofpolypeptides were found to be either
increased or decreased in their amount when comparing
parental and cisplatin-resistant cells. The most prominent
changes were observed in the soluble fraction of the cisplatin-
resistant hepatoma cell line 7404-CP20. Proteins of molecular
weights 90, 70, 52 and 50 kDa were significantly increased in
intensity as indicated by I arrows (Figure 6b) when compared
with the parental BEL-7404 cells (Figure 6a). The R arrows
in the parental BEL-7404 cells indicate the locations of pro-
teins that were reduced in the cisplatin-resistant cells.
Numerous increases or decreases in proteins could also be
detected in KB-CPr cells compared with the cisplatin-sensitive
parental KB-3-l cells as indicated by arrows I and R as
shown in Figure 6c and d respectively.
Further analyses were done on crude membrane fractions,
as shown in Figure 7. Polypeptides with increased or reduced
densities in the cisplatin-resistant cells as compared with their
sensitive parental cell lines are marked by arrows I or R
respectively. In cisplatin-resistant hepatoma cells, two
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Figure 4 Eight per cent SDS-PAGE of proteins from crude
membrane fractions followed by Coomassie blue staining. Crude
membrane fractions were prepared as described in Materials and
methods. Aliquots of 501g of protein from each cell line were
loaded. Arrows indicate the molecular mass in kDa. Note that
the 52 kDa proteins were elevated in both the 7404-CP7.5 and
KB-CPIO cells. P170 is the MDRI gene product, P-glycoprotein,
which served as a positive control for expression of this pro-
tein.
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Figure 5 Histograms showing semiquantitative changes in the
52 kDa protein in cytosolic soluble fractions (a) and in the crude
membrane fraction (b), as seen in Figure 3 and 4 respectively.
The 52 kDa protein was scanned with the AMBIS Radioanalytic
Imaging System using AMBIS QuantProbe Software.
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Figure 6 Fluorogram of two-dimensional gels of [35S]methionine-labelled cytosolic soluble proteins. (a) BEL-7404; (b) 7404-CP20;
(c) KB-3-1; and (d) KB-CP20. Cytosolic soluble fractions were prepared as described in Materials and methods. Arrows labelled I
indicate an increase in protein content in the cisplatin-resistant cells. Arrows labelled R indicate peptides which are reduced in the
CPF cells.
polypeptides of 52 and 50 kDa were increased, and five pro-
teins were decreased, as shown in Figure 7a and b. Figure 7c
and d shows two-dimensional gels of KB-3-1 and KB-CPI0
cells, in which the 1-52 and 1-50 proteins were also overexp-
ressed in the cisplatin-resistant cells.
To identify the nature of the 52 kDa protein, cytosoluble
fractions isolated from BEL-7404 and 7404-CP20 cells were
subjected to two-dimensional electrophoresis, then transblot-
ted onto polyvinylidene difluoride (PVDF) membranes. The
PVDF membranes were stained with 0.1% Coomassie brilli-
ant blue to localise the overexpressed polypeptides. The
52 kDa polypeptide spots were collected for amino acid
microsequencing. The result indicated that seven amino acids
were recognised as follows: Asp-Val-Lys-Phe-Gly-Ala-Asp.
This sequence is 100% identical to the amino terminus of the
mitochondrial matrix protein P1, also known as heat shock
protein hsp6O. Using a human specific hsp6O monoclonal
antibody and the ECL kit, Figure 8a and b show overexpres-
sion of the hsp60 in cytosolic soluble proteins and membrane
pellets in cisplatin-resistant cell lines, demonstrating a sub-
stantial increase in hsp60 in cytosolic and membrane pellet
fractions in 7404-CP20 cells. Overexpression of hsp60 could
also be detected in the KB-CP20 cells (about 2-fold higher
than the parental KB-3-1 cells). hsp70 levels (lower panels)
were generally unchanged in cisplatin-resistant cells and their
parental cells for both hepatoma and KB cell lines.
Discussion
Several different mechanisms for resistance to cisplatin have
been demonstrated during the past several years, including
decreased cross-linking of DNA, increased rates of DNA
repair (Chu and Chang, 1990), increased levels of intracel-
lular thiols and reduced accumulation of cisplatin (Richon et
al., 1987; Andrews and Howell, 1990). However, no one
mechanism has been uniformly present in all cisplatin-
resistant cells examined. In this work, we find that two
human cell lines selected for high-level resistance to cisplatin,
which also show similar patterns of cross-resistance to
methotrexate, 5-FU and 6-MP, manifest many changes in
protein levels, but share an increase in polypeptides of
molecular weight 52 and 50 kDa.
The human liver carcinoma cell line BEL-7404 was chosen
as a model system to study cisplatin resistance because of its
intrinsic resistance to this agent and in the hope that further
selection in cisplatin would amplify the effect of its intrinsic
resistance mechanism. Thus, it should be feasible to deter-
mine which biochemical alterations are responsible for the
intrinsic and acquired cisplatin resistance of these cells with
the central goal of creating sensitive molecular probes of
clinical tumour specimens. A comparison of cisplatin resis-
tance between the BEL-7404 hepatoma cells and KB-3-1
adenocarcinoma cells showed that the hepatoma cells were
about 13-fold more resistant, without selection, than the
KB-3-1 cells. After selection in cisplatin, the ICm values for
the 7404-CP7.5 cells and the KB-CP1O cells were 49 and
38 fig ml-' cisplatin respectively, which was almost one thou-
sand times higher than the parental KB-3-1 cells. We would
like to determine the basis for such high-level resistance to
cisplatin, which is not commonly seen in cell lines selected in
vitro for resistance to this agent.
It has been reported that cells acquiring cisplatin resistance
also develop resistance to alkylating agents and other types
of DNA-damaging chemicals (Frei et al., 1985). 7404-CPF
cells showed a limited degree of resistance to a bifunctional
agent, melphalan (2.6-fold), that was similar to results
previously described (Puchalski and Fahl, 1990), while the
KB-CP1O cells were about 11-fold more resistant than the
parental KB-3-1 cells. Interestingly, both 7404-CPF and KB-
CPF cells demonstrated cross-resistance to methotrexate,
about 39- and 20-fold relative to their sensitive parental cell
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Figure 7 Fluorogram of two-dimensional gels of [35S]methionine-labelled membrane proteins. (a) BEL-7404; (b) 7404-CP20; (c)
KB-3-1; and (d) KB-CP20. Cell membrane fractions were prepared as described in Materials and methods. Arrows labelled with I
or R were positioned as described in Figure 6.
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Figure 8 Immunoblot analysis of heat shock proteins with
visualisation by ECL. Cytosolic soluble proteins (a) and memb-
rane pellet fractions (b) were transblotted on nitrocellulose mem-
brane after 10% SDS-PAGE as described in Materials and
methods. Top: Protein samples were immunoreacted with mono-
clonal antibody (MAb) specific to human hsp60 (arrow). Bottom:
The same blot in upper panel was stripped and reprobed with
MAb specific to human hsp70 (arrow). Lane 1, BEL-7404; lane 2,
7404-CP20; lane 3, KB-3-1; lane 4, KB-CP20.
lines respectively. This phenomenon is consistent with the
observations on cisplatin-resistant cell lines derived from a
human squamous carcinoma, SSC-25 (Teicher et al., 1986),
and an ovarian carcinoma (Newman et al., 1988). In a recent
study on mouse Balb/3T3 cisplatin-resistant cell lines trans-
formed with human genomic DNAs isolated from human
hepatoma 7404-CP7.5 cells, cross-resistance to methotrexate
also occurred (unpublished data of the authors). The human
cisplatin-resistant hepatoma cells also showed cross-resistance
to 5-fluorouracil and 6-mercaptopurine by 23.0- and 12.9-
fold relative to the parental cells respectively. Similar patterns
but lower resistance levels to 5-fluorouracil and 6-mercap-
topurine were also found in the KB-CP1O cells.
These results suggest that this cross-resistance, particularly
to methotrexate, may be a consequence of a common, novel
mechanism of multidrug resistance. This cross-resistance may
be related to nucleotide pools since cross-resistance primarily
affects nucleotide derivatives, or could be associated with
export of drug metabolites via an ATP-dependent gluta-
thione S-conjugate export pump (Ellis, 1990; Ishikawa and
Ali-Osman, 1993). More recent data from collaborative
studies with Dr Thomas C Hamilton at Fox Chase Cancer
Center indicates that there is a 17-fold reduction in
accumulation of cisplatin in the cisplatin-resistant hepatoma
7404-CP20 cells compared with the parental sensitive cell line
BEL-7404 (SW Johnson and TC Hamilton, personal com-
munication). This result suggests that an active efflux pump
or an impaired uptake of cisplatin may exist in these
cisplatin-resistant cells (Jekunen et al., 1994).
No cross-resistance to the MDR substrates colchicine, vin-
blastine, actinomycin D, mitomycin C and VP-16, or to
non-MDR substrate hydroxyurea was found in the hepatoma
CP7.5 cells. Some cross-resistance to actinomycin D, doxo-
rubicin, mitomycin C and hydroxyurea was observed in the
KB-CPIO cells. These results support the hypothesis that
there is no single pattern of resistance associated with selec-
tion in cisplatin and that the multiple steps of selection used
in this study undoubtedly gave rise to several different resis-
tance mechanisms.
To begin our analysis of the basis of drug resistance in
these highly cisplatin-resistant human cell lines, we compared
patterns of protein expression seen in KB-CP1O and CP7.5
cells. Alterations in the steady-state amount of several
different polypeptides were repeatedly detected in both solu-
ble cytosolic and crude membrane fractions by regular SDS-
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PAGE or two-dimensional SDS-PAGE. When comparing
the differences between the cisplatin-resistant cells and their
sensitive parental cells, one feature common to 7404-CPF and
KB-CPF was the overexpression of a 52 kDa protein(s) in the
pelleted membrane and cytosolic fractions of both the hepa-
toma and the KB cisplatin-resistant cell lines. The content of
this protein(s) in crude membrane fractions increased in
parallel with increased cisplatin resistance in the 7404-CPr
cell lines, and reduced amounts were found in the revertant
KB-CP5-df365 cells which had been maintained in cisplatin-
free medium for more than 1 year. The resistance of this
KB-CP5-df365 cell line to cisplatin was remarkably reduced
from its original 788 times to 21 times higher than the
sensitive parental KB-3-1 cells. However, the 52kDa pro-
tein(s) was still increased to some extent in a partially
reverted cisplatin-resistant hepatoma cell line, 7404-CP20-
dfl55, which retained 31-fold more resistance to cisplatin
than its sensitive parental cells. This continued expression of
cisplatin resistance and of 52kDa protein(s) indicates that
cisplatin resistance is a relatively stable change in cells, and
that the increase in the 52 kDa protein(s) is also probably a
stable change rather than a transient event such as a toxic
response to cisplatin. Further evidence that the 52 kDa pro-
tein is not increased directly in response to cisplatin treat-
ment came from an experiment in which the sensitive paren-
tal BEL-7404 cells were exposed to cisplatin at 1.5 igml'
for 1, 3, and 17 h (data not shown). In this experiment, no
increase in 52 kDa proteins was observed. Compared with
KB-CPI0 cells, elevations and reductions in several other
proteins ofdifferent molecular weight were also observed, but
no other changes were shared by both the hepatoma and the
KB cell lines.
Recent studies indicate that 52 kDa protein(s) can also be
detected in primary and secondary transfectants of mouse
Balb/3T3 cells transformed to express cisplatin resistance
with high molecular weight DNA from cisplatin-resistant
human hepatoma 7404-CP7.5 cells, suggesting that the
52 kDa proteins may play a role, directly or indirectly, in
cisplatin resistance (DW Shen, I Pastan and MM Gottesman,
in preparation). Amino acid microsequencing of the 52 kDa
spots indicates that there is 100% identity for seven amino
acids to the human heat shock protein, hhsp60, a chaper-
onin. Using immunoblots reacted with a human specific
monoclonal antibody directed to hsp60 further confirmed
that heat shock protein 60 was elevated in CPF cells from
both hepatoma and KB cell lines. There were no detectable
changes in hsp7o between sensitive and CPF cell lines tested in
this study. Work by Howell's group has also identified hsp60
as a protein overexpressed in cisplatin-resistant cells (Kimura
et al., 1993). At this time, we can only speculate on the
possible functions of an elevation in hsp60 in cisplatin-
resistant human cancer cells. hsp60 is a homologue ofGroEL
and a highly conserved intrinsic mitochondrial protein. As a
member of the chaperonin family, it is generally accepted
that the hsp60 probably mediates the correct folding of
polypeptides, and in some cases their assembly into oligo-
meric structures. hsp60 may also function by binding
specifically and non-covalently to interactive protein surfaces
that are exposed transiently during cellular processes such as
protein synthesis, protein transport across membranes and
stress responses (Ellis, 1990). Whether overexpression of
hsp60 protects cells from toxic effects of cisplatin is as yet
unclear.
Of the other protein changes, only the overexpressed 1-90
protein in the soluble fractions of cisplatin-resistant cells
could be tentatively identified as a stress-related heat shock
protein, hsp90, as its isoelectric point (Figure 6b) is quite
similar to that reported for hsp90 on the two-dimensional
map of transformed amnion cells (Celis et al., 1990). The
altered expression of other proteins, in either 7404 or KB
cisplatin-resistant cells, demonstrates that profound
phenotypic alterations occurred during acquisition of resis-
tance to the agent. However, the changes in these proteins
may not be directly responsible for resistance to cisplatin, but
may reflect a response to stress and/or represent changes
needed for survival and proliferation of cells exposed to
cisplatin.
In these studies, the 200kDa protein found in cisplatin-
resistant murine lymphoma cells (Kawai et al., 1990) was not
detected in our CPT cell lines by SDS-PAGE. In addition, no
elevated expression of P-glycoprotein, the MDR1 gene pro-
duct, was found as compared with KB-C1.5, an MDR1
gene-expressing cell line. Expression of the MDR1 gene was
undetectable by Northern or RNA slot-blot hybridisation
with the specific MDR1 cDNA probe pHDR5A (Ueda et al.,
1987 and results not shown). Neither extrachromosomal
DNA (episomes) nor double minute (DM) chromosomes
could be identified by pulsed-field gradient gel electrophoresis
(PFGE) or karyotypic analysis. In addition, the native MDR
locus, which is contained within a 330 kb SfiI fragment, was
intact and unamplified as determined by PFGE analysis
(Schoenlein et al., 1992, and data not shown).
Recently, changes in DNA damage repair proteins, DNA-
binding proteins, chromosomal protein HMG1 and nuclear
matrix proteins were found in cisplatin-resistant cells (Chu
and Chang, 1990; Clugston et al., 1992; de Jong et al., 1992;
Pil and Lippard, 1992; Zhen et al., 1992). Some types of
glutathione S-transferase, glutamylcystine synthetase and
thymidylate synthetase have also been reported to increase
during development of cisplatin resistance (Behrens et al.,
1987; Scanlon and Kashani-Sabet, 1988; Puchalski and Fahl,
1990; Godwin et al., 1992). Taken together with the results in
this paper, cisplatin resistance appears to result from many
different mechanisms affecting function of the nucleus, cyto-
plasm and membranes. Which of these mechanisms is most
common and which, if any, are clinically relevant, remains to
be determined.
Abbreviations: cisplatin, cis-diamminedichloroplatinum(II); CPr, cis-
platin resistance; SDS-PAGE, sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis; DMS, double minutes (chromosomes);
EMS, ethyl methanesulphonate.
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